Prostate Cancer: Double VS triplet therapy in mHSPC - Urology Cheatsheets
Consultation Report Topic details 1. Summary 2. Background 3. Publication of consultation
Is Triple Therapy the New Standard for Metastatic Hormone-sensitive Prostate Cancer? - touchONCOLOGY
EAU 2021: Apalutamide for Metastatic Castration-Sensitive Prostate Cancer: Outcomes in High-Volume and Low-Volume Disease From the TITAN Final Analysis
Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis - European Urology Focus
Triplet Therapy Has a Place in Metastatic Hormone-Sensitive Prostate Cancer Treatment, But For Whom?
Oligometastatic Prostate Cancer: A Shrinking Subset or an Opportunity for Cure? | American Society of Clinical Oncology Educational Book
Going towards a precise definition of the therapeutic management of de-novo metastatic castration sensitive prostate cancer patients: How prognostic classification impact treatment decisions - ScienceDirect
Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis - European Urology Focus
Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer - eBioMedicine
APCCC 2019: Which Systemic Therapy for Which Patients with Newly Diagnosed Metastatic Prostate Cancer?
Computed Tomography (CT) and Bone Scans (BS) for Hormone Sensitive Prostate Cancer - YouTube
Non-systemic Treatment for Patients With Low-volume Metastatic Prostate Cancer
Prostate cancer - The Lancet
Bone Imaging in Metastatic Castration-resistant Prostate Cancer; Where do we Stand | Bentham Science
![Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram](https://www.researchgate.net/profile/Thomas-Lam-3/publication/344701128/figure/tbl1/AS:947382543978497@1602885008589/Definition-of-high-and-low-volume-and-risk-in-CHAARTED-54-56-and-LATITIDE-57-based.png "Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram")
Definition of high and low volume, and risk in CHAARTED [54-56] and... | Download Scientific Diagram
EAU 2018: Variation in Prevalence of High and Low Volume Metastatic Prostate Cancer from the Original Comparison in the STAMPEDE Trial
A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancer - ScienceDirect
Untreated Metastatic Prostate Cancer - 2021 Prostate Cancer Patient Conference - YouTube
Targeting Metastatic Hormone Sensitive Prostate Cancer: Chemohormonal Therapy and New Combinatorial Approaches | Journal of Urology
The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer | Journal of Urology
Frontiers | Comparing the Survival Outcomes of Radical Prostatectomy Versus Radiotherapy for Patients With De Novo Metastasis Prostate Cancer: A Population-Based Study
Treatment of Metastatic Prostate Cancer in 2018.,JAMA Oncology - X-MOL
Impact of high-volume disease in Asian population with newly diagnosed metastatic prostate cancer Cheng YT, Hong JH, Lu YC, Pu YS, Huang CY, Huang KH, Liu SP, Chen CH - Urol Sci
